30 KB327 KB24 KB192920262010Cvijić, MartaGeršak, KsenijaHorvat, MirjamJernejčič, PetraVerdenik, Ivanštevilka:57 straniletnik:79str. 412-418ISSN:1318-0347COBISSID:27046361URN:URN:NBN:SI:doc-S08SLS10enSlovensko zdravniško društvoZdravniški vestnikAbnormalitiesAbnormalities, Drug-InducedanomalijeAnomalije povzročene z zdraviliAntihipertenziviAntihypertensive Agentsarterijska hipertenzijaCentral Nervous SystemCentralno živčevjeDrug TherapyHipertenzijahuman pregnancyHypertensionInfant, Newborn, DiseasesnosečnostNosečnost, komplikacije kardiovaskularneNovorojenček, bolezniPre-EclampsiaPreeklampsijaPregnancy Complications, CardiovascularProteinuriaProteinurijaRetrospective StudiesRetrospektivne študijetherapyzdravljenjeAnaliza jemanja zdravil, ki se uporabljajo pri zdravljenju hipertenzivnih stanj v nosečnosti| Analysis of the intake of drugs used in hypertensive disorders during pregnancy|Background: High blood pressure and associated medical conditions occur in 6-10 % of pregnancies. Different drugs used in hypertensive disorders during pregnancy might be associated with the occurrence of congenital malformations.The purpose of this study was to evaluate the intake of drugs used in the treatment of hypertensive disorders (HD) and establish a possible association between the use of these medications in pregnancy and the occurrence of congenital malformations. Methods: The retrospective study included all women who delivered between 2002 and 2006 at the Department of Obstetrics and Gynaecology in Ljubljana. For each subject we collected family and personal medical information, data on drug exposure and on neonatal congenital malformations. We acquired data from the National Perinatal Information System and individual labour and delivery records. The research group was composed of women taking at least one of antihypertensive drugs during pregnancy, and the control group consisted of all women without the mentioned therapy. Results: In the research group, 708 mothers with complete data on the drug intake were compared to 26,027 controls. Women taking the therapy were older, had more often diabetes mellitus, chronic renal diseases, congenital heart defects and more risk factors for HD than women in the control group. An increased number of congenital malformations in newborns wasfound in women on therapy (9.6 %; p < 0.001). Congenital malformations of the cardiovascular system and the central nervous system prevailed (p < 0.001). Conclusions: Newborns of mothers in the research group had more congenital malformations. Opinions whether the main cause for the development of congenital malformations is the underlying HD, its treatment or the mutual effect of both factors are divided. A more detailed study is required in orderto accurately determine whether the risk factor is the therapy or the HD itselfTEXTznanstveno časopisjejournalsSlovenian National E-content AggregatorNational and University Library of SloveniaSlovensko zdravniško društvo